Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04008069 · ClinicalTrials.gov registry record · Phase 2
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04008069: Completed Phase 2 study, sponsored by Stanford University.
NCT04008069 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04008069, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.
Interventions
- DRUG Placebo
- DRUG Sarilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2022-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04008069
The ClinicalTrials.gov registry entry for NCT04008069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04008069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04008069 about?
NCT04008069 is a clinical study titled "Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis". The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.
What is the current status of trial NCT04008069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2019-09-03. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT04008069?
The interventions under investigation include: Placebo (DRUG), Sarilumab (DRUG).
Who is sponsoring clinical trial NCT04008069?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.